| |
June 2023 Clinical Update: CPIC Updates Guideline Regarding CYP2D6 and CYP2C19 Genotypes, and Serotonin Reuptake Inhibitor Antidepressants (SRIs)
| |
The Clinical Pharmacogenetics Implementation Consortium (CPIC) has developed an updated comprehensive guideline for the use of specific genotypes and their impact on the effectiveness and safety of serotonin reuptake inhibitor (SRI) antidepressant medications. This guideline focuses on key genetic variations, including CYP2D6 and CYP2C19 genotypes, which play a crucial role in the metabolism and response to SRIs. The CPIC guideline offers guidance on dose adjustments for individuals with specific genotypes of these enzymes, allowing clinicians to tailor treatment plans accordingly. By integrating genotyping data into clinical decision-making, the CPIC guideline aims to improve the precision of antidepressant therapy and minimize adverse effects. Implementing these recommendations may enhance treatment outcomes, reduce trial-and-error prescribing, and improve patient satisfaction by providing personalized and evidence-based care.
It is important for healthcare providers to stay updated with the CPIC guideline, as it enables them to make informed decisions regarding the use of SRIs based on individual genetic profiles. Genetics Institute of America is committed to ensuring you are aware of updated standards put forth by prestigious organizations, like CPIC, and ensuring that the panels we offer support your medical needs and your patient’s health and safety. | |
| |
Have you Seen This?:
Cost-Effectiveness of PGx Testing
Cost-effectiveness of PGx testing is changing as testing platforms become more advanced and affordable. Summarized in a recent review, studies have indicated that PGx testing can be cost-effective or cost-saving, especially when considering multigene testing panels. Read more >> | | | |
It's All in the Genes:
Improving Depression and Anxiety Treatment with PGx Testing
Approximately 16 million Americans suffer from moderate or severe depression, and the costs associated with Major Depressive Disorder exceed $210 billion annually. Antidepressants are commonly prescribed but often have low initial success rates. Read more >>
| | | |
Changing Corporate Culture:
Bring JOY Every Day
Genetics Institute of America (GIA) takes pride in the community we are a part of and has created a corporate culture that aims to play a greater role in community solutions. Local communities are suffering and, without support from their businesses, will continue to decline and waste away in paralyzing cycles of homelessness, childhood trauma and hunger. Read more >> | | | |
| |
| |
Enroll your Practice in GH-101! | |
Genetics Institute of America is actively recruiting practices to join our study, GH-101! The objective of this study is to take an integrative approach to the fields of pharmacogenomics, cancer genomics, mRNA microarrays and nutrigenomics by identifying DNA and RNA variants in persons with chronic disease. We are looking for Physicians and Physician Groups that currently treat patients with a chronic disease including: cancer, cardiac conditions, diabetes, kidney disease, PTSD. Getting your practice involved is easy and not only gets patients the individualized health information they need but allows your practice to be on the cutting edge of genetic research. | |
| |
| |
Thank you for the trust and confidence you have placed in our team here at the Genetics Institute of America. This monthly newsletter is our primary method of communicating to you important information about our testing and assays, general information about the Genetics Institute, as well as information impacting patient care and safety. If you would like to have another person in your practice receive these updates, please forward this to them so that they can subscribe.
 Ana Perez-Miranda, PhD, MDxT (AAB), MB (ASCP) Laboratory Manager and Molecular Diagnostics Supervisor Genetics Institute of America | | | |
| |
| |
| |
GIA Lab News is an educational service of Genetics Institute of America.
Genetics Institute of America is a national laboratory dedicated to heightening the awareness of early intervention and genetic screening to promote the longevity and quality of life outcomes. Our determination and research allow us to provide next generation DNA sequencing to deliver customized testing for identified genetic related cancers and other diseases. | |
| |
| |
4733 W. Atlantic Ave, Suite C16 Delray Beach, FL 33445 Phone: (833) 4GENLAB or (833) 443-6522 HIPAA Fax: (561) 354-5369
| |
You are receiving this email because you opted into receiving communications from Genetics Institute of America online or verbally on the phone, and/or maintain a professional relationship with our laboratory. From time to time, we’ll send newsletters, blog articles, and other educational clinical updates to our subscribers. We hope you find them useful. If not, you can unsubscribe from our list here.
Who do you know that needs to know? Forward this email Did someone forward this to you? Subscribe
Want to change how you receive these emails?
You can Unsubscribe or Update your preferences.
© 2023 Genetics Institute of America. All Rights Reserved.
| |
| |
.png)
